Diabetes Drugs in Spotlight at ADA Annual Meeting
Manufacturers to present data from studies of diabetes drugs at American Diabetes Association 77th Scientific Sessions.
Novo Nordisk recently announced they will be presenting data from 60 abstracts at the American Diabetes Association (ADA) 77th Scientific Sessions regarding various diabetes drugs.
Three ADA-sponsored symposia will also discuss data about insulin degludec injection (Tresiba), liraglutide (Victoza), and semaglutide.
A few highlighted studies to be presented include:
June 10, 11:30 am — 12:30 pm PT, poster presentation
- Findings from a short-term cost-effectiveness analysis of insulin degludec and liraglutide injection, 100 units/mL and 3.6-mg/mL (Xultophy 100/3.6) versus basal-bolus therapy.
June 10, 11:30 am — 12:30 pm PT, poster presentation
- Data from a real-world examination of the efficacy of switching to insulin degludec injection from a basal insulin.
June 10, 11:30 am — 12:30 pm PT, poster presentation
- Results from the SWITCH 1 and 2 trial, which compares the incidence of hypoglycemia across hypoglycemia definitions versus insulin glargine U100.
June 10, 5:45 pm — 6 pm PT, oral presentation
- Findings from the phase 3b DUAL VII clinical trial comparing the efficacy and safety of insulin degludec and liraglutide injection 100/3.6 versus basal—bolus therapy.
June 11, 12 pm — 1 pm PT, late-breaking poster presentation
- Patient reported outcomes from the DUAL VII trial comparing insulin degludec and liraglutide injection 100/3.6 versus basal—bolus treatment.
June 12, 2:15 pm — 3:15 pm PT, symposium
- Data from DEVOTE, a cardiovascular outcomes study that investigated the cardiovascular safety of insulin degludec injection compared with insulin glargine U100 in patients with type 2 diabetes at high risk of cardiovascular events.
"There continues to be a need for research and development into new treatment options for people living with diabetes, and our data that will be presented at ADA 2017 will demonstrate how Novo Nordisk is continuing to meet this need," said Todd Hobbs, vice president and chief medical officer of Novo Nordisk. "Our evolving portfolio reflects our patient-fueled approach to researching and developing a broad range of therapeutic options with data beyond A1C reduction."
